

# HIPK2-Mediated Transcriptional Control of NMDA Receptor Subunit Expression Regulates Neuronal Survival and Cell Death

Yulei Shang,<sup>1</sup> Jiasheng Zhang,<sup>1,2</sup> and Eric J. Huang<sup>1,2</sup>

<sup>1</sup>Department of Pathology, University of California–San Francisco, San Francisco, California 94143 and <sup>2</sup>Pathology Service 113B, Veterans Administration Medical Center, San Francisco, California 94121

NMDA receptors are critical for neuronal communication. Dysfunction in NMDA receptors has been implicated in neuropsychiatric diseases. While it is well recognized that the composition of NMDA receptors undergoes a GluN2B-to-GluN2A switch in early postnatal life, the mechanism regulating this switch remains unclear. Using transcriptomic and functional analyses in brain tissues from male and female *Hipk2*<sup>+/+</sup> and *Hipk2*<sup>-/-</sup> mice, we showed that the HIPK2-JNK–c-Jun pathway is important in suppressing the transcription of *Grin2a* and *Grin2c*, which encodes the GluN2A and GluN2C subunits of the NMDA receptors, respectively. Loss of HIPK2 leads to a significant decrease in JNK–c-Jun signaling, which in turn derepresses the transcription of *Grin2a* and *Grin2c* mRNA and upregulates GluN2A and GluN2C protein levels. These changes result in a significant increase of GluN2A/GluN2B ratio in synapse and mitochondria, a persistent activation of the ERK-CREB pathway and the upregulation of synaptic activity-regulated genes, which collectively contribute to the resistance of *Hipk2*<sup>-/-</sup> neurons to cell death induced by mitochondrial toxins.

**Key words:** HIPK2; JNK; NMDA receptor; subunit; survival; transcription

## Significance Statement

We identify HIPK2-JNK–c-Jun signaling as a key mechanism that regulates the transcription of NMDA receptor subunits GluN2A and GluN2C *in vivo*. Our results provide insights into a previously unrecognized molecular mechanism that control the switch of NMDA receptor subunits in early postnatal brain development. Furthermore, we provide evidence that changes in the ratio of NMDA subunits GluN2A/GluN2B can also be detected in the synapse and mitochondria, which contributes to a persistent activation of the pro-survival ERK-CREB pathway and its downstream target genes. Collectively, these changes protect HIPK2 deficient neurons from mitochondrial toxins.

## Introduction

Homeodomain interacting protein kinase 2 (HIPK2) regulates a wide range of biological processes, including tumorigenesis, vasculogenesis, tissue fibrosis, epithelial-mesenchymal transition, and neural development (Hofmann et al., 2013; Fan et al., 2014; Blaquiére and Verheyen, 2017). There are several salient features in HIPK2 that enable it to regulate such diverse biological functions. First, HIPK2 has a versatile protein–protein interacting

domain, which provides a flexible interphase to interact with a number of transcription factors and modulate gene expression in a context-dependent manner. Second, the intrinsic kinase activity in HIPK2 provides an additional mechanism that regulates the activity of HIPK2 and its downstream targets. Finally, the broad expression pattern of HIPK2 during embryogenesis and in adult animals also allows it to regulate cell growth and differentiation either as a transcriptional coactivator or corepressor depending on the signal transduction pathway upstream of HIPK2 and the downstream transcription factors with which it interacts (Blaquiére and Verheyen, 2017).

In the mouse sensory neurons, HIPK2 interacts with POU homeodomain transcription factor Brn3a and suppresses the expression of pro-survival genes *trkA* (*Ntrk1*) and *bcl-xl* (*bcl2l1*) (Wiggins et al., 2004). HIPK2 can also interact with Smad transcription factors to promote the pro-survival signals downstream of TGF- $\beta$  and BMP in ventral midbrain dopaminergic (DA) neurons and enteric neurons (Zhang et al., 2007; Chalazonitis et al., 2011). Given these cell type-specific functions, loss of HIPK2 results in more sensory neurons and a significant reduction in the number

Received Dec. 20, 2017; revised Feb. 1, 2018; accepted Feb. 20, 2018.

Author contributions: Y.S., J.Z., and E.J.H. designed research; Y.S. and J.Z. performed research; Y.S., J.Z., and E.J.H. analyzed data; Y.S., J.Z., and E.J.H. wrote the paper.

This work was supported by National Institutes of Health Grant NS098516 and Department of the Veterans Affairs Grant BX001108. The contents do not represent the views of the U.S. Department of Veterans Affairs or the U.S. Government. We thank Dr. Phil Soriano for providing the *R26R* constructs; Dr. Guangwei Wei for help with the generation of the *R26R*<sup>HIPK2</sup> allele; Ivy Hsieh for assistance with immunogold EM; and members of the E.J.H. laboratory for feedback during the course of this study.

The authors declare no competing financial interests.

Correspondence should be addressed to Dr. Eric J. Huang, Department of Pathology, University of California–San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143. E-mail: eric.huang2@ucsf.edu.

DOI:10.1523/JNEUROSCI.3577-17.2018

Copyright © 2018 the authors 0270-6474/18/384006-14\$15.00/0

of DA neurons and enteric neurons during embryonic development and in early postnatal life. In addition to the important role of HIPK2 under physiological conditions, several studies show that HIPK2 can be activated by stress conditions to promote cell death via the ataxia telangiectasia mutated or c-Jun N-terminal kinase (JNK) pathway in tumor cells and neurons (Hofmann et al., 2003; Choi et al., 2013; Lee et al., 2016). In particular, endoplasmic reticulum (ER) stress, induced either pharmacologically by tunicamycin or by the accumulation of misfolded SOD1<sup>G93A</sup> proteins, activates a series of protein kinases downstream of inositol-requiring enzyme 1 $\alpha$ , including apoptosis signal-regulating kinase 1, HIPK2, and JNK, to promote cell death in spinal motor neurons (Lee et al., 2016). Inhibition of HIPK2 kinase activity or loss of HIPK2 protects neurons from ER stress-induced cell death and delays disease onset and prolongs survival in SOD1<sup>G93A</sup> mice (Lee et al., 2016). Together, these results highlight the role of HIPK2 in diverse pathophysiological conditions and the need to investigate the mechanisms of HIPK2 in a context-dependent fashion.

Given the role of HIPK2 in transducing the prosurvival signal of TGF- $\beta$  in embryonic DA neurons (Zhang et al., 2007; Luo and Huang, 2016), we ask how loss of HIPK2 might impact on the maintenance of ventral midbrain DA neurons in the postnatal brain. By comparing the transcriptomes of ventral midbrain in adult *Hipk2*<sup>+/+</sup> and *Hipk2*<sup>-/-</sup> mice, we uncover a previously unappreciated role of HIPK2 in regulating the subunit composition of NMDA receptors in the substantia nigra as well as several different regions in the postnatal brain. Bioinformatics data show that the majority of HIPK2 target genes contain an overrepresented number of binding motifs for AP-1 transcription factors in the promoter regions. Consistent with this idea, HIPK2 suppresses c-Jun-mediated transcription of mouse *Grin2a* and *Grin2c* genes, which encode the GluN2A and GluN2C subunits of the NMDA receptors (Collingridge et al., 2009). Loss of HIPK2 leads to an upregulation of GluN2A and GluN2C and increases the GluN2A/GluN2B ratio and the ERK-CREB signaling pathway in early postnatal brain. These changes promote the upregulation of several activity-regulated inhibitors of death (*AID*) genes and enhance the survival of *Hipk2*<sup>-/-</sup> DA neurons in mitochondrial toxin-induced cell death. Together, these results support a novel role of HIPK2 in the transcriptional regulation of NMDA receptor subunits via the JNK–c-Jun signaling pathway.

## Materials and Methods

**Animals.** *Hipk2*<sup>-/-</sup> mice (*Hipk2*<sup>tm1Ejh/Hipk2</sup><sup>tm1Ejh</sup>, RRID:MGI:5008273 and RRID:MGI:3510466) have been described previously (Wiggins et al., 2004; Zhang et al., 2007). *Hipk2*<sup>+/+</sup> and *Hipk2*<sup>-/-</sup> mice in the mixed C67BL/6 and 129 background were used at postnatal day 0 (P0), P14, P28, 2 months, and 6 months. *TH-IRES-Cre* mice (*Th*<sup>tm1(cre)Tc</sup>, MGI catalog #3056580) were previously described (Lindeberg et al., 2004; Tang et al., 2009). *R26R<sup>HIPK2</sup>* mice were generated as described in Fig. 8-1 (available at <https://doi.org/10.1523/JNEUROSCI.3577-17.2018f8-1>). Mice of both genders were selected and assigned to each age or treatment group randomly. Animal care was approved by the Institutional of Animal Care and Use Committee at the University of California–San Francisco and followed the National Institutes of Health guidelines.

**Cell cultures, transfection, and luciferase reporter assays.** HEK293 and COS-7 cells were obtained from ATCC. *Hipk2*<sup>+/+</sup> and *Hipk2*<sup>-/-</sup> mouse embryonic fibroblasts (MEFs) (Wei et al., 2007; Shang et al., 2013) were maintained in DMEM (Thermo Scientific) supplemented with 10% FBS (Invitrogen). All cell lines were authenticated and verified to be free of mycoplasma contamination. To investigate the transcriptional control of *Grin2a* and *Grin2c*, 2 kb sequences of the mouse *Grin2a* or 2.9 kb sequences of the mouse *Grin2c* promoter were amplified from mouse genomic DNA using the PCR and inserted into pGL4.10 vector to generate the *Grin2a*-Luc

and *Grin2c*-Luc reporters. A series of deletions in *Grin2a*-Luc and *Grin2c*-Luc were performed using QuikChange Site-Directed Mutagenesis kit (Stratagene), and all constructs were confirmed by DNA sequencing. The luciferase constructs, c-Jun or/and HIPK2 expression plasmids, along with the Renilla firefly internal control constructs were transfected into COS-7 cells. Cells were harvested for luciferase activity measurement (dual luciferase, Promega) or for Western blot analyses. The luciferase reporter activity was measured using the dual-luciferase system on a luminometer (Turner Designs). Relative luciferase activity was reported as a ratio of firefly over Renilla luciferase activities.

**RNA isolation, microarray, and data analysis.** Total RNA was extracted from the substantia nigra of 2-month-old *Hipk2*<sup>+/+</sup> and *Hipk2*<sup>-/-</sup> mouse brain ( $n = 3$  for each genotype) using PicoPure™ RNA Isolation Kit (Arcturus) and used as a template for reverse transcriptase with MessageAmp™ II-Biotin enhanced Kit (Ambion). Microarray analysis was performed using CodeLink Mouse Whole Genome Bioarray (Applied Microarrays). The microarray data are being deposited in Gene Expression Omnibus (<http://www.ncbi.nlm.nih.gov/geo/>); the accession number will be provided once available. Resulting data were log transformed and uploaded into the Genesifter program (a web-based expression analysis software with statistical and visual tools, [www.genesifter.com](http://www.genesifter.com)). Differences in gene expression were identified by using a minimal threshold value of a twofold change with no maximal threshold value. Based on the Genesifter analyses, the genes that show differential expression by microarray were uploaded on to DAVID bioinformatics resources. The functional annotation chart and clustering analysis modules were used to determine gene-term enrichment scores. To find the different transcriptional factor binding motif of HIPK2 targets, we analyzed 2 kb promoter sequence of HIPK2 target genes that were within the three clusters: membrane, channel, and transporter and cell–cell junction with online software Cluster-buster (<http://zlab.bu.edu/cluster-buster/>). The RNA from HEK293T cells, MEF cells, mouse cortex, or midbrain was isolated by Trizol reagent (Invitrogen) and used as a template for reverse transcriptase with random hexamer primers (Invitrogen). Primer sequences for specific genes are given in Table 1-1 (available at <https://doi.org/10.1523/JNEUROSCI.3577-17.2018t1-1>).

**Chromatin immunoprecipitation (ChIP) assays.** ChIP assays were performed as described previously (Shang et al., 2013). Briefly, 2-month-old mice were perfused and fixed with 4% PFA and treated with SDS lysis buffer. After shearing with a sonicator and centrifugation, the supernatant of cell lysates was used for immunoprecipitation with different antibodies. The DNA protein–antibody complexes were isolated using antibodies for HIPK2 (c-15, sc-110294), c-Jun (H-179, SC-1694) (Santa Cruz Biotechnology), and Smad2/3 (#3102, Cell Signaling Technology). The complexes were washed with buffers, and the DNA was eluted and purified. qRT-PCR was used to analyze the DNA abundance in protein-DNA precipitates. qRT-PCR primer sequences are given in Table 1-1 (available at <https://doi.org/10.1523/JNEUROSCI.3577-17.2018t1-1>).

**Primary cortical and dopaminergic (DA) neuron cultures.** Primary cortical neurons were prepared from the cerebral cortex of E17.5 mouse embryos and placed in MEM supplemented with 10% FBS, 1 $\times$  penicillin/streptomycin, and 2 mM glutamine (Invitrogen). On *in vitro* day 2 (DIV2), 5 mM 5-fluoro-2'-deoxyuridine (Sigma) was added to the cultures. From DIV3, the primary cortical neurons were maintained in Neurobasal medium with B-27 supplement (Invitrogen). On DIV14, the cells were fixed with cold methanol for 15 min, followed by immunofluorescent staining with GluN2A or GluN2B antibody (NR2a, Code #GluRe1C-Rb-Af542; NR2b, Code #GluRe2N-Rb-Af660, Frontier Institute). Primary DA neurons were prepared according to published procedures (Zhang et al., 2007). Briefly, E13.5 *Hipk2*<sup>+/+</sup> and *Hipk2*<sup>-/-</sup> mouse embryos were collected from time-pregnant *Hipk2*<sup>+/-</sup> females. The ventral mesencephalon was dissected, dissociated after treatment with trypsin, and cultured in DMEM-F12 medium (Invitrogen #11765–054) supplemented with 10% FBS, 1 $\times$  penicillin/streptomycin, and 2 mM glutamine (Invitrogen) on cover slides coated with poly-DL-ornithine hydrobromide (Sigma-Aldrich, catalog #P8638) and laminin (Sigma-Aldrich, catalog #L2020) overnight. On DIV2, the medium was replaced with DMEM-F12 medium supplemented with 10% FBS, 20 ng/ml FGF2, 100 ng/ml FGF8, and 1 $\times$  penicillin/streptomycin for 2 d. The cells were either treated with 0.5

nM carbonyl cyanide *m*-chlorophenyl hydrazone (CCCP) directly or pretreated with GluN2A inhibitor NVP-AAM077 (Calbiochem, catalog #CAS459836-30-7) or ERK1/2 inhibitor SCH-772984 (AbMole Bioscience, catalog #M2084) for 4 h, then treated with CCCP for 20 h. The cells were fixed with 4% PFA for 10 min and stained with anti-TH antibody (Millipore Bioscience Research Reagents, catalog #AB152) or anti-Tuj1 antibody (Covance, catalog #PRB-435P) following the standard staining procedures. Confocal images of the cultured neurons were captured using the confocal microscope (TCS SP, Leica). Laser intensity (measured as the PMT levels) for each fluorophore was kept within the linear range. TH<sup>+</sup> or NeuN<sup>+</sup> Cell number was determined by National Institutes of Health ImageJ online software.

**Immunogold electron microscopy.** Mice were deeply anesthetized with avertin (150 mg/kg) and were perfused transcardially with 2% PFA/0.2% glutaraldehyde in 0.1 M phosphate buffer at pH 7.4 with gravity. Brains were quickly removed, fixed overnight in 2% PFA at 4°C, and cut into 60- $\mu$ m-thick frontal sections with vibratome. To enhance the penetration of the immunoreagents, the sections were equilibrated in a cryoprotectant solution, freeze-thawed, and stored in PBS with 0.03% sodium azide. After blocked with 4% normal goat serum in PBS, the sections were incubated with primary antibody in 1% normal goat serum blocking solution overnight (NR2a, Code #GluRe1C-Rb-Af542; NR2b, Code #GluRe2N-Rb-Af660, Frontier Institute). After washed with washing buffer (PBS with 0.2% BSA and 0.2% fish gelatin), the samples were incubated with secondary antibody conjugated to gold particles (Electron Microscopy Sciences, catalog #25100, or GAR, Ultra Small, Code 100,011) in washing solution for 2 h, and refixed with 1% glutaraldehyde in PBS 10 min. The signal of the immunogold particles was boosted using R-gent SE-EM silver enhancement solution (Aurion, 500.033). Finally, the sections were postfixed in 0.5% osmium tetroxide for 10 min, dehydrated, and embedded in resin (Durcupan ACM, Sigma-Aldrich). Serial ultrathin sections were cut with a Reichert Ultracut S, contrasted with lead citrate. Ultrathin sections were cut at 1  $\mu$ m thick with a Reichert Ultracut S, contrasted with lead citrate, and imaged in a Phillips Tecnai10 transmission electron microscope using FEI software.

**Western blot analysis and synaptosomal fractionation.** Total cell lysates were prepared from cultured cells in NP-40 lysis buffer (1% NP-40, 20 mM Tris, pH 7.6, 150 mM NaCl, 10 mM NaF, 1 mM Na<sub>3</sub>VO<sub>4</sub>) supplemented with protease inhibitor mixture. RIPA buffer (0.1% SDS, 1% sodium deoxycholate, 1% NP-40, 20 mM Tris, pH 7.6, 150 mM NaCl, 10 mM NaF, 1 mM Na<sub>3</sub>VO<sub>4</sub>) supplemented with protease inhibitor mixture was used for protein extraction from tissues. Proteins in cell lysates were separated by SDS-PAGE and transferred to the PVDF membrane (Millipore Bioscience Research Reagents). The membrane was blocked in 4% BSA (for phosphor antibodies) or 5% nonfat milk for nonphosphorylated antibodies before incubation with primary antibodies overnight at 4°C. Antibodies to p-JNK (9255), p-c-Jun (9164), JNK (9252), c-Jun (9165), p-ERK1/2 (4370), ERK1/2 (9102), CREB (9197), p-CaMKII (3361), and CaMKII (3362) were from Cell Signaling Technology. p-CREB was from Millipore Bioscience Research Reagents (06-519). Anti-TH antibody was from Millipore Bioscience Research Reagents (AB152) and Tuj1 antibody from Covance (PRB-435P). Actin antibody (CP01) was from Calbiochem. HIPK2 antibody was purchased from Santa Cruz Biotechnology (sc-10294) or Abcam (ab28507). The membranes were washed with 0.1% TBST washing buffer followed by incubation with secondary antibodies conjugated with HRP. Western blots were developed by ECL chemiluminescence (Thermo Scientific).

To characterize the GluN2A, GluN2B, and GluN2C protein level in synapses, the synaptosomes were isolated from 2-month-old *Hipk2*<sup>+/+</sup> and *Hipk2*<sup>-/-</sup> mouse brains as described previously (Carlin et al., 1980). Briefly, mouse brains without cerebellums were homogenized in buffer A (0.32 M sucrose, 1 mM NaHCO<sub>3</sub>, 1 mM MgCl<sub>2</sub>, 0.5 mM CaCl<sub>2</sub>, 5 mM NaF, and 2 mM Na<sub>3</sub>VO<sub>4</sub>, supplemented with protease inhibitor, at a ratio of 4 ml/g of brain tissue) using a Dounce tissue grinder (Kontes glass homogenizer No 20, 12 strokes). Cell debris were removed by centrifugation at 710  $\times$  g for 10 min at 4°C. The pellet was suspended with 3 strokes in solution A, and then the nuclear fraction was removed by centrifugation at 1400  $\times$  g for 10 min at 4°C. The crude membrane fraction in the supernatant was collected by centrifugation at 13,800  $\times$  g for 10 min at

4°C. The pellet (crude synaptosomal fraction) was suspended in solution B (0.32 M sucrose, 1 mM NaHCO<sub>3</sub>, 5 mM NaF, and 2 mM Na<sub>3</sub>VO<sub>4</sub>, 3.2 ml/g of starting tissue) with 6 strokes of homogenizer. The resulting supernatant was collected and separated on a discontinuous sucrose gradient (1.2 M, 1 M, and 0.8 M) by centrifugation at 82,500  $\times$  g with a Beckman SW55Ti rotor at 4°C for 2 h. Following centrifugation, cytosolic, synaptosomal, and mitochondrial fractions were collected from top to bottom. Equal aliquots from individual fractions were separated by SDS-PAGE and analyzed by immunoblotting with antibodies for PSD95, synaptophysin (SPH), GluN2A, GluN2B, GluN2C, and actin.

**Chronic MPTP exposure in *Hipk2*<sup>+/+</sup>, *Hipk2*<sup>-/-</sup>, and *TH-IRES-Cre; R26R*<sup>HIPK2/HIPK2</sup> mice.** MPTP (4 mg/kg, Sigma-Aldrich catalog #M103) or equivalent volume of PBS was injected intraperitoneally into 2-month-old male and female mice (littermates) by one injection per day for 10 consecutive days. The mice were monitored according to the approved Institutional of Animal Care and Use Committee protocol, and their health was scored before each injection. Seven days after the last MPTP treatment, mice were killed and perfused with 4% PFA before brain extraction. The brains were postfixed in 4% PFA overnight, followed by serial cryoprotection in 15% and 30% sucrose for 24 h each. The brains were embedded for cryosectioning and cut into 40  $\mu$ m coronal sections. The sections containing the substantia nigra pars compacta were stained using anti-TH (Millipore Bioscience Research Reagents, catalog #AB152) and the staining results developed with DAB. Stereological counting was used to quantify the number of TH-positive cells in the substantia nigra pars compacta (single hemisphere) at bregma -2.8 to -4.04 mm (6 serial sections) at 60 $\times$  magnification using the StereoInvestigator Software, version 9 (MBF Bioscience) according to the protocols previously reported (Zhang et al., 2007; Martens et al., 2012).


**Experimental design and statistical analyses.** For both *in vivo* and *in vitro* studies, at least three biological replicates were used in each study. In experiments in which *N* was >3, the exact number of replicates will be indicated. Data were analyzed by two-tailed Student's *t* test for pairwise comparisons or two-way ANOVA for multiple comparisons using Prism (GraphPad Software). All data were expressed as mean  $\pm$  SEM. For stereology counting, investigators were blinded to the genotypes.

## Results

### Loss of HIPK2 increases *Grin2a* and *Grin2c* genes expression

To characterize how loss of HIPK2 affects the long-term survival of DA neurons, we compared the transcriptomes of substantia nigra microdissected from 2-month-old *Hipk2*<sup>+/+</sup> and *Hipk2*<sup>-/-</sup> mice, and found 279 upregulated and 256 downregulated genes in *Hipk2*<sup>-/-</sup> mice (Table 1-2, available at <https://doi.org/10.1523/JNEUROSCI.3577-17.2018>). Functional annotations using DAVID Gene Ontology (GO) analyses showed that the upregulated genes belonged to 10 groups, including membrane functions, synaptic transmission and ion channel, regulation of growth, cell fraction, cellular junction, regulation of transport and endocytosis, vesicles, immunity and inflammatory response, extracellular origin, and lymphocyte homeostasis (Fig. 1A). In contrast, most of the GO clusters of the downregulated genes showed very low enrichment scores; therefore, only two functional categories were identified among these genes, including cell death and intermediate filament.

Of the upregulated genes in *Hipk2*<sup>-/-</sup> mice, we focused on two NMDA receptor subunits, *Grin2a* and *Grin2c*, because they were the top hits in the upregulated GO categories and because both have well-established prosurvival functions (Hardingham and Bading, 2010; Paoletti et al., 2013). To validate the microarray data, we used qRT-PCR to show that both *Grin2a* and *Grin2c* were indeed upregulated in the substantia nigra and cerebral cortex of *Hipk2*<sup>-/-</sup> mice (Fig. 1B,C). Consistent with microarray data, there was no significant difference in *Grin2b* mRNA level. The upregulation of *Grin2a* in postnatal brain appeared to be stage-dependent. In the substantia nigra, *Grin2a* mRNA was ele-




**Figure 1.** Transcriptomic analyses of the substantia nigra in adult *Hipk2*<sup>-/-</sup> mouse brain. **A**, DAVID GO analyses showed the 12 groups of the upregulated and downregulated genes in the substantia nigra of 2-month-old *Hipk2*<sup>-/-</sup> mice. **B**, **C**, *Grin2a* and *Grin2c* mRNA levels were upregulated in the substantia nigra and cerebral cortex of 2-month-old *Hipk2*<sup>-/-</sup> mice, whereas the *Grin2b* mRNA expression was similar between *Hipk2*<sup>+/+</sup> and *Hipk2*<sup>-/-</sup> mice. **D**, **E**, *Grin2a* mRNA was elevated in the substantia nigra of *Hipk2*<sup>-/-</sup> from postnatal day 0 (P0) until 2 months old. However, in the cerebral cortex, *Grin2a* mRNA started to increase from P20 to adulthood. **F**, **G**, *Grin2a* and *Grin2c* mRNA levels were also robustly increased in *Hipk2*<sup>-/-</sup> MEFs, and blocking of HIPK2 kinase activity by its specific inhibitors enhanced *Grin2a* and *Grin2c* expression in MEF cells. Data are mean  $\pm$  SEM from at least three independent experiments. \* $p$  < 0.05 (ANOVA). \*\* $p$  < 0.01 (ANOVA). Not significant:  $p$  > 0.05.

vated in *Hipk2*<sup>-/-</sup> mice as early as postnatal day 0 (P0) and persisted until 2 months of age. By 6 months of age, there was no difference in *Grin2a* mRNA levels in the substantia nigra of *Hipk2*<sup>+/+</sup> and *Hipk2*<sup>-/-</sup> mice (Fig. 1D). In contrast, *Grin2a* mRNA levels in the cerebral cortex showed no difference between *Hipk2*<sup>+/+</sup> and *Hipk2*<sup>-/-</sup> mice at P0 and P14 but were significantly higher in *Hipk2*<sup>-/-</sup> cortex from P28 to 6 months of age (Fig. 1E). Interestingly, *Grin2a* and *Grin2c* mRNA levels were also robustly increased in *Hipk2*<sup>-/-</sup> MEFs. Furthermore, treating *Hipk2*<sup>+/+</sup> MEF with HIPK2 inhibitors, A64 and CP466722 (Miduturu et al., 2011; Lee et al., 2016), was sufficient to upregulate *Grin2a* and *Grin2c* mRNA levels (Fig. 1F,G). Together, these results revealed a broader role of HIPK2 in the transcription of NMDA receptor subunits in postnatal brain development and in non-neuronal cells.

#### HIPK2 suppresses *Grin2a* and *Grin2c* gene expression via AP-1 transcription factor c-Jun

Given the previously reported role of HIPK2 as a transcriptional cosuppressor or coactivator in a variety of signaling pathways, we

hypothesized that HIPK2-dependent expression of *Grin2a* and *Grin2c* is likely mediated through transcription factors that directly bind to the promoter and/or enhancer elements of *Grin2a* and *Grin2c* genes. To test this, we procured 2 kb genomic DNA sequence upstream of the transcriptional start sites in 130 HIPK2 target genes in the top three GO categories, including “cell–cell junction,” “membrane,” and “ion channel and transport” (Table 1–3, available at <https://doi.org/10.1523/JNEUROSCI.3577-17.2018>), and analyzed them with the Cluster-Buster software (Frith et al., 2003). Our goal was to identify consensus transcription factor binding elements that were shared among the HIPK2 target genes. Of all the transcription factors binding elements annotated in Cluster Buster, the AP-1 binding motif was overrepresented in the 2 kb promoter/enhancer sequences of HIPK2 target genes, with 3–4 AP-1 binding motifs per gene (Fig. 2A). In contrast, the binding motifs for other transcription factors were significantly fewer, ranging from 1 or 2 per gene. Further annotations of all the AP-1 binding motif in HIPK2 target genes revealed a highly conserved TGA core sequence in positions 3–5,



**Figure 2.** Characterizations of HIPK2 as a transcriptional repressor of c-Jun in the transcriptional control of mouse *Grin2a* and *Grin2c* genes. **A, B**, Compared with the DNA binding motifs for other transcription factors, the AP-1 binding motif was overrepresented and showed a highly conserved binding core sequence, in the 2 kb promoter/enhancer sequences of HIPK2 target genes. **C, D**, Luciferase activities of both *Grin2a*-Luc and *Grin2c*-Luc were suppressed by c-Jun, and the transcriptional suppressor activity of c-Jun in *Grin2a*-Luc and *Grin2c*-Luc reporters can be further enhanced by the addition of HIPK2 (Figure 2–1, available at <https://doi.org/10.1523/JNEUROSCI.3577-17.2018f2-1>). **E, F**, Western blot showed the expression of the exogenous HIPK2 and c-Jun constructs, and the endogenous actin protein level. The results showed that HIPK2 kinase dead mutant, HIPK2<sup>K221A</sup>, was unable to promote the c-Jun-mediated suppression, indicating that the kinase is required for its cosuppressor function. **G–I**, ChIP assays showed that the endogenous c-Jun was bound to the AP-1 motif in the promoters of *Grin2a* and *Grin2c* in 2-month-old *Hipk2*<sup>+/+</sup> mouse brain. In contrast, the same promoter regions in *Grin2a* and *Grin2c* showed much lower binding of transcription factors Smad2/3 and SP-1. Loss of HIPK2 decreased the binding between c-Jun and the conserved AP-1 binding motif in the promoter/enhancer sequences of *Grin2a* and *Grin2c*. Data are mean ± SEM from at least three independent experiments. \**p* < 0.05 (ANOVA). \*\**p* < 0.01 (ANOVA). Not significant: *p* > 0.05.

flanked by more flexible nucleotide sequences at both 5' and 3' ends (Fig. 2B).

The identification of AP-1 binding motifs in HIPK2 target genes is in agreement with our recent data that HIPK2 promotes ER stress-mediated cell death via the JNK–c-Jun signaling pathway (Lee et al., 2016). To characterize the role of AP-1 binding motifs in *Grin2a* and *Grin2c*, we generated luciferase reporters that contained the 2 kb upstream sequence of *Grin2a* or 2.9 kb upstream sequence of *Grin2c* gene. These two reporters, named *Grin2a*-Luc and *Grin2c*-Luc, respectively, were then used as surrogates to determine how HIPK2 and c-Jun regulate the transcription of *Grin2a* and *Grin2c*. Consistent with the microarray data, our results showed that c-Jun suppressed the luciferase activities of both *Grin2a*-Luc and *Grin2c*-Luc, whereas HIPK2 worked cooperatively with c-Jun to further suppress *Grin2a*-Luc and *Grin2c*-Luc (Fig. 2C,D). Interestingly, HIPK2 alone also suppressed *Grin2a*-Luc and *Grin2c*-Luc reporter activities, probably due to the high endogenous c-Jun levels in COS-7 cells (Fig. 2-1, available at <https://doi.org/10.1523/JNEUROSCI.3577-17.2018f2-1>). In contrast, transcription factors and cofactors, such as MEF2C and HDAC7, which can interact with HIPK2 and regulate vasculogenesis during embryonic development (Shang et al., 2013), did not affect *Grin2a*-Luc and *Grin2c*-Luc reporter activities (Fig. 2-1, available at <https://doi.org/10.1523/JNEUROSCI.3577-17.2018f2-1>).

A series of deletions in *Grin2a*-Luc and *Grin2c*-Luc showed that, of the 8 AP-1 binding sites in *Grin2a* promoter, the one closest to the transcriptional start site was required for c-Jun and HIPK2 to suppress *Grin2a*-Luc. Similarly, of the 4 AP-1 binding sites in *Grin2c*-Luc, the two closest to transcriptional start site were required for c-Jun and HIPK2 to suppress *Grin2c*-Luc. In addition, we showed that the kinase activity of HIPK2 was required for HIPK2 to promote c-Jun-mediated suppression because the kinase dead form of HIPK2 (HIPK2-K221A) was unable to suppress *Grin2a*-Luc or *Grin2c*-Luc activity, even in the presence of c-Jun (Fig. 2E,F). The cooperative effects of HIPK2 and c-Jun in suppressing *Grin2a*-Luc and *Grin2c*-Luc reporter activities were summarized using downward arrows to the right of the schematic diagrams in Figure 2C, D. To further characterize how HIPK2 and c-Jun regulate *Grin2a* and *Grin2c* gene expression, we performed ChIP assays using native chromatin extracts from 2-month-old *Hipk2*<sup>+/+</sup> mouse brain, and detected binding of the endogenous c-Jun, Smad2/3, and SP1 proteins to the *Grin2a* and *Grin2c* promoters (Fig. 2G). In contrast, there was significantly less c-Jun binding to the *Grin2a* and *Grin2c* promoters in the chromatin from *Hipk2*<sup>-/-</sup> mouse brain (Fig. 2H,I). These results supported the role of HIPK2 as a cosuppressor of c-Jun in the transcriptional control of *Grin2a* and *Grin2c* gene expression.

### Increased GluN2A and GluN2A/GluN2B ratio in the synaptosomes of *Hipk2*<sup>-/-</sup> mouse brain


Having demonstrated the increased *Grin2a* and *Grin2c* mRNA in the substantia nigra and cerebral cortex of *Hipk2*<sup>-/-</sup> mice, we next asked whether there were also increases in GluN2A and GluN2C protein levels. Because NMDA receptors are enriched in synapses, we isolated synaptosomes from the cerebral cortex of 2-month-old *Hipk2*<sup>+/+</sup> and *Hipk2*<sup>-/-</sup> mice (Carlin et al., 1980) (Fig. 3-1, available at <https://doi.org/10.1523/JNEUROSCI.3577-17.2018f3-1>) and used Western blots to detect the relative abundance of GluN2A and GluN2C proteins (Fig. 3A). The results showed that GluN2A and GluN2C protein levels were indeed increased in the synaptosomes of cerebral cortex *Hipk2*<sup>-/-</sup> mice, whereas GluN2B protein level was decreased (Fig. 3A,B). These changes led to >2-fold increase in the ratio of GluN2A versus GluN2B in the

synaptosomes of *Hipk2*<sup>-/-</sup> mice (Fig. 3C). To further characterize this phenotype, we prepared primary cortical neuron cultures from embryonic day 17.5 (E17.5) *Hipk2*<sup>+/+</sup> and *Hipk2*<sup>-/-</sup> embryos. These neurons were cultured for 14 d (DIV14) and then stained with antibodies that were specific for GluN2A or GluN2B, and the presynaptic protein, SPH. Consistent with the Western blot data, confocal microscopy showed that the number of GluN2A<sup>+</sup> puncta in *Hipk2*<sup>-/-</sup> dendrites were 31.2% (23.9 vs 18.2) more abundant than that in *Hipk2*<sup>+/+</sup> dendrites (Fig. 3D,E,H), whereas the number of GluN2B<sup>+</sup> puncta was decreased in *Hipk2*<sup>-/-</sup> dendrites (Fig. 3F–H). Interestingly, in *Hipk2*<sup>+/+</sup> dendrites, the percentage of GluN2A<sup>+</sup> and GluN2B<sup>+</sup> puncta that were also positive for presynaptic marker SPH was 31.2% and 33.8%, respectively. In contrast, the percentage of GluN2A<sup>+</sup>;SPH<sup>+</sup> synapse on the dendrites of *Hipk2*<sup>-/-</sup> neurons increased to 60.1%, whereas the percentage of GluN2B<sup>+</sup>;SPH<sup>+</sup> synapse reduced to 10.3% (Fig. 3I). Consistent with these results, immunogold electron microscopy performed on the sensorimotor cortex using GluN2A or GluN2B antibody showed higher percentage of GluN2A<sup>+</sup> synapse but reduced GluN2B<sup>+</sup> synapse per unit area in *Hipk2*<sup>-/-</sup> brain (Fig. 3J–O). Finally, using similar approaches, we also found a significant increase in GluN2A proteins and a decrease in GluN2B proteins in the synaptosomes prepared from the substantia nigra of *Hipk2*<sup>-/-</sup> mouse brain (Fig. 3P–R). Together, these results support the idea that loss of HIPK2 has a broader effect on the levels of GluN2A and GluN2B in multiple areas in the mouse brain.

### Altered JNK and ERK-CREB signaling pathways in *Hipk2*<sup>-/-</sup> mouse brain

In the canonical JNK–c-Jun signaling pathway, diverse upstream signals activate JNK kinase activity, which in turn phosphorylates c-Jun to regulate the transcription of AP-1 target genes. Our recent study shows that HIPK2 can activate JNK under ER stress to promote neuronal cell death (Lee et al., 2016). In addition, results in Figure 2 indicate that HIPK2 facilitates c-Jun binding to *Grin2a/2c* promoter and functions as a cosuppressor to regulate *Grin2a* and *Grin2c* transcription in a kinase-dependent manner. Together, these results suggest that HIPK2-mediated JNK–c-Jun phosphorylation and activation may be required for transcriptional control of *Grin2a* and *Grin2c*. To test this, we prepared protein lysates from substantia nigra, sensorimotor cortex, spinal cord, and MEF cells, and analyzed the relative abundance of p-JNK and p-c-Jun in *Hipk2*<sup>+/+</sup> and *Hipk2*<sup>-/-</sup> tissues using Western blot. As predicted, there was a consistent reduction in the levels of p-JNK and p-c-Jun in tissues from different regions of *Hipk2*<sup>-/-</sup> mouse brain, but no significant reduction in the level of total c-Jun or JNK (Fig. 4A,B). Interestingly, *Hipk2*<sup>-/-</sup> MEF cells also showed significant reductions in p-c-Jun and p-JNK, although the decrease in p-c-Jun was much more drastic compared with tissues from *Hipk2*<sup>-/-</sup> mouse brain (Fig. 4A,B). Consistent with the Western blot results, immunofluorescent microscopy showed a significant reduction of p-c-Jun staining intensity in the nuclei of *Hipk2*<sup>-/-</sup> dopaminergic neurons compared with that in *Hipk2*<sup>+/+</sup> neurons (Fig. 4C,D,G). In contrast, no significant reduction of p-Smad2 was detected in the dopaminergic neurons of *Hipk2*<sup>-/-</sup> mice (Fig. 4E–G).

Previous studies showed that activation of extrasynaptic GluN2B triggers calcium accumulation in mitochondria that is strongly associated with mitochondrial swelling and neuronal cell death. In contrast, activation of GluN2A at the synapse provides a prosurvival mechanism by activating the ERK-CREB signaling pathway to promote the expression of prosurvival genes (Hardingham and




**Figure 3.** Increased expression of GluN2A and GluN2C proteins in the synapses of *Hipk2*<sup>-/-</sup> mouse brain. **A–C**, Western blots using the total cell lysates, cytosolic fraction, and the synaptosomes from 2-month-old *Hipk2*<sup>+/+</sup> and *Hipk2*<sup>-/-</sup> mouse brain showed that GluN2A and GluN2C protein levels were increased in the synaptosomes of cerebral cortex in *Hipk2*<sup>-/-</sup> mice, whereas GluN2B protein level was decreased, leading to a significant increase in the GluN2A/GluN2B ratio in the cerebral cortex in *Hipk2*<sup>-/-</sup> mice (Figure 3–1, available at <https://doi.org/10.1523/JNEUROSCI.3577-17.2018f3-1>). The relative signal intensity of GluN2A, GluN2B, and GluN2C protein bands was quantified with National Institutes of Health ImageJ software. **D–I**, Confocal microscopic images of the primary cortical neuron cultures showed that the number of GluN2A<sup>+</sup> puncta in the dendrites of *Hipk2*<sup>-/-</sup> neurons were 31.2% more, whereas the GluN2B<sup>+</sup> puncta were 40% less, abundant than that in the dendrites of *Hipk2*<sup>+/+</sup> neurons. Interestingly, the percentage of GluN2A<sup>+</sup>SPH<sup>+</sup> synapse increased to 60.1%, whereas the percentage of GluN2B<sup>+</sup>SPH<sup>+</sup> synapse reduced to 10.3% on the dendrites of *Hipk2*<sup>-/-</sup> neurons. The GluN2A<sup>+</sup> or GluN2B<sup>+</sup> puncta were quantified with National Institutes of Health ImageJ online software. **J–O**, Immunogold electron microscopy performed in the sensorimotor cortex of 2-month-old *Hipk2*<sup>+/+</sup> and *Hipk2*<sup>-/-</sup> brains showed more GluN2A<sup>+</sup> synaptic terminals, but fewer GluN2B<sup>+</sup> synaptic terminals in *Hipk2*<sup>-/-</sup> mutants. Overall, there was a higher percentage of GluN2A<sup>+</sup> synapse, but lower percentage of GluN2B<sup>+</sup> synapse in the sensorimotor cortex in *Hipk2*<sup>-/-</sup> mouse brain. **P–R**, Western blots showed a significant increase in GluN2A proteins and a decrease in GluN2B proteins in the synaptosomes from the substantia nigra of 2-month-old *Hipk2*<sup>-/-</sup> mouse brain. The signal intensity of GluN2A, GluN2B, and actin was quantified with National Institutes of Health ImageJ software. Data are mean ± SEM from at least three independent experiments. \**p* < 0.05 (ANOVA). \*\**p* < 0.01 (ANOVA). Not significant: *p* > 0.05.

Bading, 2010). Given the increased ratio of GluN2A/GluN2B in the synapses of *Hipk2*<sup>-/-</sup> neurons, we asked whether loss of HIPK2 might alter the activation of ERK and CREB. To test this, we first examined the state of CaMKII activation, which is the major downstream kinase regulated by the synaptic calcium influx, and found no difference in the level of phosphorylated CaMKII and total CaMKII between *Hipk2*<sup>+/+</sup> and *Hipk2*<sup>-/-</sup> brain tissues or synaptosomes (Fig. 5–1, available at <https://doi.org/10.1523/JNEUROSCI.3577-17.2018f5-1>). However, loss of HIPK2 resulted in an elevated level of p-ERK and p-CREB in the protein lysates from substantia nigra, sensorimotor cortex, spinal cord, and MEF cells, without altering the total level of ERK or CREB (Fig. 5A,B). Consistent with these results, confocal microscopy showed a significant increase in the relative signal intensity for p-CREB in TH<sup>+</sup> DA neurons in the substantia nigra of *Hipk2*<sup>-/-</sup> mouse brain (Fig. 5C).

As a prototypical signal-regulated transcription factor, CREB regulates a number of target genes that are critical for neuronal survival, synaptic plasticity, and learning and memory. Comprehensive whole-genome transcriptome profiling has identified a

number of nuclear Ca<sup>2+</sup>-regulated genes, termed *AID* genes, which have been shown to provide neurons with broad-spectrum neuroprotective effects both in cultured cells and in animal models of neurodegeneration (Lau and Bading, 2009; Zhang et al., 2009). Given that some of the *AID* genes are potential CREB target genes, we reasoned that the elevated level of p-CREB in *Hipk2*<sup>-/-</sup> brain tissues might increase the expression of *AID* genes. In support of this idea, qRT-PCR analyses using mRNA from the substantia nigra and cerebral cortex of 2-month-old *Hipk2*<sup>+/+</sup> and *Hipk2*<sup>-/-</sup> mice showed consistent upregulation of several *AID* genes, including *Btg2*, *Gadd45 g*, *Gadd45b*, *Serp1b2*, *Bcl6*, *Cyr61*, *Arc*, *Jun B*, and *Bdnf* (Fig. 5D,E). Upregulation of a similar set of *AID* genes was also identified in *Hipk2*<sup>-/-</sup> MEF cells (Fig. 5F). These results support the idea that loss of HIPK2 increases CREB phosphorylation and promotes the transcription of CREB target genes, including many *AID* genes.

**Increased GluN2A in the mitochondria of *Hipk2*<sup>-/-</sup> neurons**  
Functional NMDA receptors, including GluN1 and GluN2A, have been identified on mitochondria in neurons and play a neu-




**Figure 4.** Reduced activation of the JNK–c-Jun signaling pathway in *Hipk2*<sup>-/-</sup> mouse brain. **A, B**, Western blots using lysates from the cerebral cortex, substantia nigra, and spinal cord of 2-month-old *Hipk2*<sup>+/+</sup> and *Hipk2*<sup>-/-</sup> mice showed a consistent reduction in the levels of p-JNK and p-c-Jun, but no changes in total JNK and c-Jun. Similar results were identified in Western blots using protein lysates from *Hipk2*<sup>-/-</sup> MEF cells. The signal intensity of p-c-Jun, p-JNK, c-Jun, and JNK bands was quantified with National Institutes of Health ImageJ online software. **C–F**, Confocal microscopy of p-c-Jun and p-Smad2 expression in DA neurons of 2-month-old *Hipk2*<sup>+/+</sup> and *Hipk2*<sup>-/-</sup> mice. **G**, Quantification of p-c-Jun and p-Smad2 fluorescent signal intensity in **C–F**. Data are mean ± SEM from at least three independent experiments. \**p* < 0.05 (ANOVA). \*\**p* < 0.01 (ANOVA). \*\*\**p* < 0.001 (ANOVA). Not significant: *p* > 0.05.

roprotective role during injury (Zipfel et al., 2000; Korde and Maragos, 2012). Given the increased GluN2A protein level in the synaptosomes of *Hipk2*<sup>-/-</sup> brain, we asked whether there was also a similar increase of GluN2A in the mitochondria. To test this, we used sucrose density gradients to purify mitochondria from 2-month-old *Hipk2*<sup>+/+</sup> and *Hipk2*<sup>-/-</sup> mouse brains (Fig. 3-1, available at <https://doi.org/10.1523/JNEUROSCI.3577-17.2018f3-1>). Consistent with the prediction, GluN2A protein level showed a significant increase in the mitochondria isolated from *Hipk2*<sup>-/-</sup> mouse brain, whereas GluN2B protein level was decreased (Fig. 6A,B). Similar changes in GluN2A and GluN2B protein level were also observed in mitochondria isolated from *Hipk2*<sup>-/-</sup> MEF cells (Fig. 6A–C). To provide morphological evidence supporting the increase of GluN2A in mitochondria, we performed immunogold electron microscopy and showed that the majority of GluN2A<sup>+</sup> and GluN2B<sup>+</sup> immunogold particles were located on the outer membrane of the mitochondria (Fig. 6D–G). Consistent with the Western blot results, the percentage of GluN2A<sup>+</sup> mitochondria was indeed increased in *Hipk2*<sup>-/-</sup> neurons (Fig. 6H). Although the percentage of GluN2B<sup>+</sup> mitochondria seemed decreased, the extent of reduction did not reach statistical significance.

#### Blocking GluN2A or ERK reverses *Hipk2*<sup>-/-</sup> DA neuron resistance to mitochondrial toxin

Our results thus far indicate that changes in the JNK–c-Jun and ERK–CREB pathways, upregulation of *AID* genes, and the increase of GluN2A in the mitochondria of *Hipk2*<sup>-/-</sup> neurons may render these neurons more resistant to mitochondrial toxins. In support of this idea, our results showed that primary *Hipk2*<sup>-/-</sup> DA neurons were more resistant to CCCP, which inhibited oxidative phosphorylation in the mitochondria by uncoupling the proton gradient (Fig. 7A–D,I,J). To characterize the role of GluN2A in the CCCP-resistant properties in *Hipk2*<sup>-/-</sup> neurons, we treated both *Hipk2*<sup>+/+</sup> and *Hipk2*<sup>-/-</sup> DA neurons with 5-phosphonomethylquinoxalinedione derivative (NVP-AAM077), which is a selective antagonist of GluN2A (>100-fold over GluN2B) (Auberson et al., 2002). Consistent with our prediction, blocking GluN2A with NVP-AAM077 increased the sensitivity of *Hipk2*<sup>-/-</sup> DA neurons to CCCP-mediated toxicity. Interestingly, under NVP-AAM077 treatment, *Hipk2*<sup>-/-</sup> DA neurons were still more resistant to CCCP toxicity than *Hipk2*<sup>+/+</sup> neurons (Fig. 7E,F,I). These results suggested that, in addition to the increase in GluN2A protein levels in the synaptosomes and mitochondria, additional unknown mechanism(s), which could upregulate the






**Figure 5.** Enhanced activation of the ERK-CREB signaling pathway in *Hipk2*<sup>-/-</sup> mouse brain. **A, B**, Western blots using protein lysates from the substantia nigra, sensorimotor cortex, and spinal cord of 2-month-old *Hipk2*<sup>+/+</sup> and *Hipk2*<sup>-/-</sup> mice showed elevated levels of p-ERK and p-CREB in *Hipk2*<sup>-/-</sup> mouse brains, without altering the total level of ERK or CREB. Similar results were identified in cell lysates from *Hipk2*<sup>-/-</sup> MEF cells (Figure 5–1, available at <https://doi.org/10.1523/JNEUROSCI.3577-17.2018f5-1>). The signal intensity of p-ERK, total ERK, p-CREB, total CREB, and actin was quantified with National Institutes of Health ImageJ software. **C**, Confocal microscopy showed a significant increase in the relative signal intensity for p-CREB in TH<sup>+</sup> DA neuron in the substantia nigra of *Hipk2*<sup>-/-</sup> mouse brain. The signal intensity of p-CREB puncta was quantified with National Institutes of Health ImageJ software. **D–F**, qRT-PCR analyses using mRNA from the substantia nigra and cerebral cortex of 2-month-old *Hipk2*<sup>+/+</sup> and *Hipk2*<sup>-/-</sup> mice showed consistent upregulation of several *AID* genes, and the similar *AID* genes could also be identified in *Hipk2*<sup>-/-</sup> MEF cells. Data are mean ± SEM from at least three independent experiments. \**p* < 0.05 (ANOVA). \*\**p* < 0.01 (ANOVA). \*\*\**p* < 0.001 (ANOVA). Not significant: *p* > 0.05.

ERK-CREB signaling, might also contribute to the resistance of *Hipk2*<sup>-/-</sup> DA neurons to CCCP. To test this, we treated *Hipk2*<sup>+/+</sup> and *Hipk2*<sup>-/-</sup> DA neurons with SCH772984, which has nanomolar potency in blocking ERK kinase activity in cancer cells (Morris et al., 2013). Similar to GluN2A inhibitor NVP-AAM077, ERK inhibitor SCH772984 dose-dependently restored the sensitivity of *Hipk2*<sup>-/-</sup> DA neurons to CCCP-mediated toxicity. Interestingly, unlike NVP-AAM077, SCH772984 normalized the differences in CCCP toxicity between *Hipk2*<sup>+/+</sup> and *Hipk2*<sup>-/-</sup> DA neurons (Fig. 7G,H,I). Together, these pharmacological data from GluN2A inhibitor NVP-AAM077 and ERK inhibitor SCH772984 supported the model that the upregulation of GluN2A and activation the ERK-CREB signaling pathway in *Hipk2*<sup>-/-</sup> DA neurons cooperatively contribute to the resistance of these neurons to CCCP-induced mitochondrial toxicity (Fig. 7K).

**Dosage-dependent effects of HIPK2 in MPTP toxicity in DA neurons**

To characterize the role of HIPK2 in neuronal cell death *in vivo*, we generated a conditional HIPK2 “knock-in” allele by inserting EGFP-HIPK2 cDNA into the ROSA26 (*R26R*) locus (Fig. 8-1, available at <https://doi.org/10.1523/JNEUROSCI.3577-17.2018f8-1>). This allele, named *R26R*<sup>HIPK2</sup>, provides the advantage of expressing additional HIPK2 proteins in ventral midbrain DA neurons using *TH-IRES-Cre* (Tang et al., 2009) (Fig. 8-2, available at <https://doi.org/10.1523/JNEUROSCI.3577-17.2018f8-2>). To determine how HIPK2 affects neuronal cell death induced by mitochondrial toxins *in vivo*, we developed a chronic treatment paradigm by intraperitoneally injecting 2-month-old *Hipk2*<sup>+/+</sup>, *Hipk2*<sup>-/-</sup>, and *TH-IRES-Cre;R26R*<sup>HIPK2/HIPK2</sup> mice with MPTP (4 mg/kg) once daily for 10 d. Seven days after the last injection, mice were killed for quantification of DA neuron deficits using stereology (Dauer



**Figure 6.** Altered GluN2A/GluN2B protein ratio in the mitochondria of *Hipk2*<sup>-/-</sup> mouse brain. **A**, Western blot results showed that the GluN2A protein level was significantly increased, whereas the GluN2B protein level was decreased, in the mitochondria isolated from the whole brain of 2-month-old *Hipk2*<sup>-/-</sup> mice (top) or from *Hipk2*<sup>-/-</sup> MEF cells (bottom). **B, C**, The relative signal intensity of GluN2A, GluN2B, and Vdac1 (a mitochondria-specific marker) protein bands in *Hipk2*<sup>+/+</sup> and *Hipk2*<sup>-/-</sup> mouse brains and in *Hipk2*<sup>+/+</sup> and *Hipk2*<sup>-/-</sup> MEF cells was quantified with National Institutes of Health ImageJ software, and reported in **B** and **C**, respectively. **D–I**, Immunogold electron microscopy results showed that the percentage of GluN2A<sup>+</sup> mitochondria was indeed increased in *Hipk2*<sup>-/-</sup> neurons, which were mainly located on the outer membrane of the mitochondria. Arrows indicate the GluN2A- or GluN2B-positive mitochondria. Data are mean ± SEM from at least three independent experiments. \**p* < 0.05 (ANOVA). Not significant: *p* > 0.05.

and Przedborski, 2003; Martens et al., 2012). In *Hipk2*<sup>+/+</sup> mice, chronic MPTP treatment resulted in ~40% reduction in the number of DA neurons in the substantia nigra (Fig. 8A, B, G). Although the number of DA neurons in the substantia nigra of *Hipk2*<sup>-/-</sup> mice was lower than in *Hipk2*<sup>+/+</sup> littermates (Zhang et al., 2007), there was no reduction of DA neurons in *Hipk2*<sup>-/-</sup> mice after the same MPTP treatment, supporting the idea that the majority of *Hipk2*<sup>-/-</sup> DA neurons were resistant to MPTP-induced toxicity (Fig. 8C, D, G). Interestingly, expressing additional HIPK2 in DA neurons in *TH-IRES-Cre;R26R<sup>HIPK2/HIPK2</sup>* mice increased their vulnerability to MPTP toxicity, leading to a much more severe loss of DA neurons in the substantia nigra than that in *Hipk2*<sup>+/+</sup> mice (Fig. 8E–G). Finally, to characterize the effect of MPTP in the JNK–c-Jun signaling, we quantified the signal intensity of p-c-Jun in the DA neurons using confocal microscopy. In PBS-injected mice, there was a slight reduction of p-c-Jun in the DA neurons of *Hipk2*<sup>-/-</sup> mice, whereas the levels of p-c-Jun in the DA neurons were similar between *Hipk2*<sup>+/+</sup> and *TH-IRES-Cre;R26R<sup>HIPK2/HIPK2</sup>* mice (Fig. 8H–J, N). Consistent with the essential role of HIPK2 in JNK–c-Jun activation (Fig. 4) (Lee et al., 2016), MPTP treatment significantly increased the p-c-Jun signal intensity in the DA neurons of *Hipk2*<sup>+/+</sup> and even more so in *TH-IRES-Cre;R26R<sup>HIPK2/HIPK2</sup>* mice, but no detectable increase in the DA neurons in *Hipk2*<sup>-/-</sup> mice (Fig. 8K–N).

## Discussion

One important feature of NMDA receptors is its complex and dynamic changes in the subunit composition, which contributes to synaptic maturation, plasticity, and diversity (Paoletti et al., 2013). Although it is well recognized that the composition of NMDA receptors undergoes a switch from predominantly GluN2B subunit during embryonic brain development to GluN2A subunit in early postnatal life (the GluN2B-to-GluN2A switch), the molecular mechanism regulating this switch remains poorly understood. Using brain region-specific transcriptomic analyses, we have uncovered a previously unappreciated role of the HIPK2–JNK–c-Jun pathway in suppressing the transcription of the *Grin2a* and *Grin2c* genes, which encode NMDA receptor subunits GluN2A and GluN2C, respectively, in early postnatal brain development in mice. First, using bioinformatics, luciferase reporters, and bio-


chemical and genetic approaches, we showed that HIPK2 is a transcriptional corepressor to suppress the expression of *Grin2a* and *Grin2c*. Loss of HIPK2 leads to a significant decrease in the JNK–c-Jun signaling pathway, increases in *Grin2a* and *Grin2c* mRNA due to reduced transcriptional repression by c-Jun, and an upregulation of GluN2A and GluN2C protein levels in DA neurons in the substantia nigra and neurons in the cerebral cortex. Second, in agreement with these findings, ultrastructural and biochemical analyses show that the increase in GluN2A results in a significant increase of GluN2A/GluN2B ratio in synapse and mitochondria, a persistent activation of the ERK–CREB pathway, and the upregulation of several prosurvival Ca<sup>2+</sup>-regulated genes (Fig. 7K). Finally, pharmacological approaches showed that *Hipk2*<sup>-/-</sup> DA neurons were more resistant to neurotoxin CCCP, and that this resistance can be reversed by GluN2A inhibitor NVP-AAM077 or ERK1/2 inhibitor SCH-772984. Together, these results provide strong evidence supporting the resistance of *Hipk2*<sup>-/-</sup> neurons to cell death induced by mitochondrial toxins.

The GluN2B-to-GluN2A switch in postnatal brain development is highly evolutionarily conserved from amphibians to mammals and is considered an important mechanism that has profound impacts from synapse maturation to associative learning (Dumas, 2005). In addition, this switch contributes to changes in the biophysical and pharmacological properties of NMDA receptors. Our results provide both *in vitro* and *in vivo* evidence that the HIPK2–JNK–c-Jun signaling pathway regulates the GluN2B-to-GluN2A switch in postnatal brain development via transcriptional control of *Grin2a* and *Grin2c*. These findings are complementary to the previously reported role of transcriptional repressor element-1 silencing transcription factor, which uses an epigenetic remodeling mechanism to suppress the transcription of *Grin2b* in the hippocampal synapses during postnatal development in rats (Rodenäs-Ruano et al., 2012). Although our study does not directly investigate the effect of HIPK2 on *Grin2a* and *Grin2c* expression in the hippocampal synapses, given their ubiquitous expression in brain, it is plausible that HIPK2 and repressor element-1 silencing transcription factor may be critical components of an integral mechanism that cooperatively regulates the GluN2A-to-GluN2B switch during synapse maturation

in postnatal brain development. With the inherent differences in the biophysical properties of GluN2A and GluN2B, it is conceivable that changes in GluN2A/GluN2B ratio in *Hipk2*<sup>-/-</sup> mouse brain may alter the GluN1/GluN2A diheteromeric and GluN1/GluN2A/GluN2B triheteromeric composition in synapses in substantia nigra and cerebral cortex.


The identification of HIPK2-JNK-c-Jun pathway as a key mechanism that regulates the GluN2B-to-GluN2A switch has important functional implications because perturbations to this switch have been implicated in many neuropsychiatric disorders. For instance, the Rett syndrome gene *MECP2* has cell type-specific effects in regulating the NMDA receptor subunit composition in visual cortex during postnatal development (Durand et al., 2012). In mouse models, loss of *Mecp2* leads to a premature NMDA receptor maturation with more abundant GluN2A on the parvalbumin<sup>+</sup> interneurons and regression in vision (Mierau et al., 2016). Interestingly, reducing GluN2A expression in *Mecp2*<sup>-/-</sup> mice alleviates the decline in visual function, suggesting that targeting NMDA subunit composition might provide feasible therapeutic targets for Rett syndrome. Interestingly, a recent forward genetic screen in human kinases and phosphatases for druggable regulators of MeCP2 stability identifies HIPK2 and protein phosphatase PP2A as strong candidates that can stabilize MeCP2 protein levels *in vivo* (Lombardi et al., 2017). These results further reinforce the important role of HIPK2 in regulating the GluN2B-to-GluN2A switch in the context of neurodevelopmental diseases, such as Rett syndrome. In addition, we have recently shown that the autocrine TGF- $\beta$  signaling in ventral midbrain DA neurons is critical to maintain a balanced excitation-inhibition synaptic input. Loss of TGF- $\beta$  Type II receptor in DA neurons reduces excitatory input and alters the phasic firing pattern in these neurons. As a consequence, mice lacking TGF- $\beta$  Type II receptor in DA neurons (*DAT-iCre;Tbr1<sup>fl/fl</sup>*) exhibit hyperactivity and reward learning deficits (Luo et al., 2016). Given the important role of HIPK2 in TGF- $\beta$ /BMP signaling pathway (Zhang et al., 2007; Chalazonitis et al., 2011), it is very likely that reduced HIPK2-mediated regulation of NMDA receptor subunit expression may contribute to the synaptic and behavioral changes in *DAT-iCre;Tbr1<sup>fl/fl</sup>* mice.

Aside from its critical roles in synaptic transmission, neurotoxicity mediated by NMDA receptors has been implicated in the pathogenesis of neurodegenerative diseases. In Alzheimer's disease



**Figure 7.** Pharmacological characterizations of CCCP-induced mitochondrial toxicity in *Hipk2*<sup>-/-</sup> DA neurons. **A–J**, Primary DA neurons from *Hipk2*<sup>-/-</sup> mice were more resistant to mitochondrial toxicity induced by CCCP than *Hipk2*<sup>+/+</sup> DA neurons. CCCP toxicity in neurons was quantified by the percentage of surviving TH<sup>+</sup> neurons based on confocal microscopy. Although blocking GluN2A with NVP-AAM077 increased the sensitivity of *Hipk2*<sup>-/-</sup> DA neurons to CCCP-mediated toxicity, the treated neurons were still more resistant to CCCP toxicity than *Hipk2*<sup>+/+</sup> neurons. ERK inhibitor SCH772984 completely eliminated the resistance of *Hipk2*<sup>-/-</sup> DA neurons to CCCP-mediated toxicity. Data are mean  $\pm$  SEM from at least three independent experiments. \* $p$  < 0.05 (ANOVA). \*\* $p$  < 0.01 (ANOVA). \*\*\* $p$  < 0.001 (ANOVA). Not significant:  $p$  > 0.05. **K**, Schematic diagram depicting the working model by which the HIPK2-JNK pathway regulates c-Jun-mediated suppression of *Grin2a* and *Grin2c* in *Hipk2*<sup>+/+</sup> neurons, which maintain the GluN2A/GluN2B ratio to regulate synaptic transmission and Ca<sup>2+</sup>-mediated ERK-CREB signaling pathway. Loss of HIPK2 or inhibition HIPK2 kinase activity by its specific inhibitors reduces JNK-c-Jun signaling, which derepresses the transcription of *Grin2a* and *Grin2c*, alters the GluN2A/GluN2B ratio, and activates ERK-CREB signal pathway that promotes the expression of *AID* genes to promote the survival of *Hipk2*<sup>-/-</sup> neurons in toxicity-induced by mitochondrial toxin CCCP.

model, GluN2B has been shown to mediate amyloid  $\beta$ -mediated perturbation of LTP and synaptic loss (Hu et al., 2009; Li et al., 2011; Röncke et al., 2011). In patients with Parkinson's disease, the degeneration of DA neurons in the substantia nigra is associ-



**Figure 8.** Essential role of HIPK2 in mitochondrial toxin-mediated cell death in DA neurons. **A–F**, TH immunohistochemical stain highlights the ventral midbrain DA neurons in 2-month-old *Hipk2*<sup>+/+</sup>, *Hipk2*<sup>-/-</sup>, and *TH-IRES-Cre;R26R*<sup>HIPK2/HIPK2</sup> mice that received intraperitoneal injection of PBS or MPTP (Figure 8–1 available at <https://doi.org/10.1523/JNEUROSCI.3577-17.2018f8-1>). **G**, Stereology counting of DA neuron number shows that MPTP causes ~41% reduction in DA neurons in the substantia nigra of *Hipk2*<sup>+/+</sup> mice, no reduction in the DA neurons in *Hipk2*<sup>-/-</sup> mice, and a much more severe reduction in DA neurons in *TH-IRES-Cre;R26R*<sup>HIPK2/HIPK2</sup> mice (Figure 8–2, available at <https://doi.org/10.1523/JNEUROSCI.3577-17.2018f8-2>). **H–M**, Immunofluorescent confocal microscopy shows the staining of p-Jun in TH<sup>+</sup> DA neurons in the substantia nigra of 2-month-old *Hipk2*<sup>+/+</sup>, *Hipk2*<sup>-/-</sup>, and *TH-IRES-Cre;R26R*<sup>HIPK2/HIPK2</sup> mice treated with either PBS or MPTP. **K, M**, Arrowheads indicate the TH<sup>+</sup> neurons in *Hipk2*<sup>+/+</sup> and *TH-IRES-Cre;R26R*<sup>HIPK2/HIPK2</sup> mice show more intense p-c-Jun staining. **N**, Relative signal intensity of p-c-Jun in TH<sup>+</sup> DA neurons is quantified with National Institutes of Health ImageJ software. Results are from at least 3 mice in each condition and genotype. Data are mean ± SEM from at least three independent experiments. \**p* < 0.05 (paired Student's *t* test). \*\*\**p* < 0.001 (paired Student's *t* test). \*\*\*\**p* < 0.0005. Not significant: *p* > 0.05.

ated with an overactivation of the glutaminergic projection to the striatum and basal ganglia output nuclei (Sgambato-Faure and Cenci, 2012). Several plausible mechanisms have been proposed to explain the potential contributions of NMDA receptor in these disease settings. First, excessive Ca<sup>2+</sup> influx through NMDA receptors causing Ca<sup>2+</sup> overload can be deleterious to neurons. Second, activation of the synaptic and extrasynaptic NMDA receptors can promote distinct signaling pathways that contribute to neuronal survival and cell death, respectively. Finally, activation of GluN2A-containing NMDA receptors can provide pro-survival effects in cultured neurons and in stroke models via CREB signaling pathway (Liu et al., 2007; von Engelhardt et al., 2007; Chen et al., 2008; Terasaki et al., 2010). Our results show that the reduced JNK–c-Jun signaling in the substantia nigra and cerebral cortex in *Hipk2*<sup>-/-</sup> mice is accompanied by a robust increase in the relative abundance of GluN2A and an increase in GluN2A/GluN2B ratio. In addition, the same brain regions in *Hipk2*<sup>-/-</sup> mice show a robust increase in ERK–CREB signaling

and upregulation of several *AID* genes. These results are consistent with previous reports (Liu et al., 2007; von Engelhardt et al., 2007; Chen et al., 2008; Terasaki et al., 2010) and support the idea that the increase in GluN2A subunit, CREB signaling, and the expression of *AID* genes collectively contribute to the resistance of *Hipk2*<sup>-/-</sup> DA neurons to CCCP- and MPTP-induced neuronal toxicity. This idea is further supported by the pharmacological inhibition of GluN2A and ERK1/2, which reverses the resistance of *Hipk2*<sup>-/-</sup> DA neurons to CCCP.

Recent studies show that NMDA agonists can also increase the Ca<sup>2+</sup> level in isolated brain mitochondria, which attenuates ROS-induced cytochrome *c* release and cell death induced by exposure to excessive glutamate (Korde and Maragos, 2012, 2016). Given the beneficial effects of GluN2A in mitochondria, it is tempting to speculate that the increase of GluN2A and reduced GluN2B in the mitochondria of *Hipk2*<sup>-/-</sup> brains might also contribute to the resistance of *Hipk2*<sup>-/-</sup> DA neurons to mitochondrial toxins CCCP and MPTP. However, it will require more in-depth anal-

yses of mitochondrial physiology in *Hipk2*<sup>-/-</sup> neurons to determine (1) how an increase in GluN2A alters mitochondrial membrane potentials under resting condition or when exposed to CCCP, and (2) whether GluN2A-independent mechanism(s) might contribute to the resistance of *Hipk2*<sup>-/-</sup> neurons to mitochondrial toxins.

In conclusion, our investigation on the transcriptomes of the substantia nigra in adult *Hipk2*<sup>-/-</sup> mice reveals an unexpected mechanism for HIPK2 in the transcriptional control of NMDA receptor subunits GluN2A and GluN2C. Together with our previous study (Zhang et al., 2007), these results support the idea that HIPK2 is a transcriptional cofactor that has stage- and context-dependent role in regulating TGF- $\beta$ -dependent survival of DA neurons during embryonic development and maturation of NMDA receptors in the same neurons in early postnatal life. This mechanism appears to have a broader role in neurons in different brain regions, including the substantia nigra, cerebral cortex, and spinal cord. These results are in agreement with our recent study that ER stress, induced by pharmacological agents or by the accumulation of misfolded proteins, activates a cascade of kinases downstream of inositol-requiring enzyme 1 $\alpha$ , including apoptosis signal-regulating kinase 1, HIPK2, and JNK, to promote cell death in neurons, MEFs, and HEK293 cells (Lee et al., 2016). Genetically removal of *Hipk2* or blocking HIPK2 kinase activation using HIPK2 kinase inhibitors protects ER stress-induced neuronal cell death. Based on the results from our current study, it is possible that, during ER stress, the activation of HIPK2–JNK–c-Jun signaling might suppress the transcription of *Grin2a* and *Grin2c*, which can alter the GluN2A-to-GluN2B ratio and potentially contribute to synaptic maturation in early postnatal brain development, as well as neuronal cell death under stress conditions.

## References

- Auberson YP, Allgeier H, Bischoff S, Lingenhoehl K, Moretti R, Schmutz M (2002) 5-Phosphonomethylquinolinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition. *Bioorg Med Chem Lett* 12:1099–1102. [CrossRef Medline](#)
- Blaquiere JA, Verheyen EM (2017) Homeodomain-interacting protein kinases: diverse and complex roles in development and disease. *Curr Top Dev Biol* 123:73–103. [CrossRef Medline](#)
- Carlin RK, Grab DJ, Cohen RS, Siekevitz P (1980) Isolation and characterization of postsynaptic densities from various brain regions: enrichment of different types of postsynaptic densities. *J Cell Biol* 86:831–845. [CrossRef Medline](#)
- Chalazonitis A, Tang AA, Shang Y, Pham TD, Hsieh I, Setlik W, Gershon MD, Huang EJ (2011) Homeodomain interacting protein kinase 2 regulates postnatal development of enteric dopaminergic neurons and glia via BMP signaling. *J Neurosci* 31:13746–13757. [CrossRef Medline](#)
- Chen M, Lu TJ, Chen XJ, Zhou Y, Chen Q, Feng XY, Xu L, Duan WH, Xiong ZQ (2008) Differential roles of NMDA receptor subtypes in ischemic neuronal cell death and ischemic tolerance. *Stroke* 39:3042–3048. [CrossRef Medline](#)
- Choi DW, Na W, Kabir MH, Yi E, Kwon S, Yeom J, Ahn JW, Choi HH, Lee Y, Seo KW, Shin MK, Park SH, Yoo HY, Isono K, Koseki H, Kim ST, Lee C, Kwon YK, Choi CY (2013) WIP1, a homeostatic regulator of the DNA damage response, is targeted by HIPK2 for phosphorylation and degradation. *Mol Cell* 51:374–385. [CrossRef Medline](#)
- Collingridge GL, Olsen RW, Peters J, Spedding M (2009) A nomenclature for ligand-gated ion channels. *Neuropharmacology* 56:2–5. [CrossRef Medline](#)
- Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. *Neuron* 39:889–909. [CrossRef Medline](#)
- Dumas TC (2005) Developmental regulation of cognitive abilities: modified composition of a molecular switch turns on associative learning. *Prog Neurobiol* 76:189–211. [CrossRef Medline](#)
- Durand S, Patrizi A, Quast KB, Hachigian L, Pavlyuk R, Saxena A, Carninci P, Hensch TK, Fagioli M (2012) NMDA receptor regulation prevents regression of visual cortical function in the absence of *Mecp2*. *Neuron* 76:1078–1090. [CrossRef Medline](#)
- Fan Y, Wang N, Chuang P, He JC (2014) Role of HIPK2 in kidney fibrosis. *Kidney Int Suppl* 4:97–101. [CrossRef Medline](#)
- Frith MC, Li MC, Weng Z (2003) Cluster-buster: finding dense clusters of motifs in DNA sequences. *Nucleic Acids Res* 31:3666–3668. [CrossRef Medline](#)
- Hardingham GE, Bading H (2010) Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. *Nat Rev Neurosci* 11:682–696. [CrossRef Medline](#)
- Hofmann TG, Stollberg N, Schmitz ML, Will H (2003) HIPK2 regulates transforming growth factor-beta-induced c-jun NH(2)-terminal kinase activation and apoptosis in human hepatoma cells. *Cancer Res* 63:8271–8277. [Medline](#)
- Hofmann TG, Glas C, Bitomsky N (2013) HIPK2: a tumour suppressor that controls DNA damage-induced cell fate and cytokinesis. *Bioessays* 35:55–64. [CrossRef Medline](#)
- Hu NW, Klyubin I, Anwy R, Rowan MJ (2009) GluN2B subunit-containing NMDA receptor antagonists prevent abeta-mediated synaptic plasticity disruption in vivo. *Proc Natl Acad Sci U S A* 106:20504–20509. [CrossRef Medline](#)
- Korde AS, Maragos WF (2012) Identification of an N-methyl-D-aspartate receptor in isolated nervous system mitochondria. *J Biol Chem* 287:35192–35200. [CrossRef Medline](#)
- Korde AS, Maragos WF (2016) Direct exposure to N-methyl-D-aspartate alters mitochondrial function. *Neurosci Lett* 623:47–51. [CrossRef Medline](#)
- Lau D, Bading H (2009) Synaptic activity-mediated suppression of p53 and induction of nuclear calcium-regulated neuroprotective genes promote survival through inhibition of mitochondrial permeability transition. *J Neurosci* 29:4420–4429. [CrossRef Medline](#)
- Lee S, Shang Y, Redmond SA, Urisman A, Tang AA, Li KH, Burlingame AL, Pak RA, Jovičić A, Gitler AD, Wang J, Gray NS, Seeley WW, Siddique T, Bigio EH, Lee VM, Trojanowski JQ, Chan JR, Huang EJ (2016) Activation of HIPK2 promotes ER stress-mediated neurodegeneration in amyotrophic lateral sclerosis. *Neuron* 91:41–55. [CrossRef Medline](#)
- Li S, Jin M, Koeglperger T, Shepardson NE, Shankar GM, Selkoe DJ (2011) Soluble abeta oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. *J Neurosci* 31:6627–6638. [CrossRef Medline](#)
- Lindeberg J, Usoskin D, Bengtsson H, Gustafsson A, Kylberg A, Söderstrom S, Ebendal T (2004) Transgenic expression of cre recombinase from the tyrosine hydroxylase locus. *Genesis* 40:67–73. [CrossRef Medline](#)
- Liu Y, Wong TP, Aarts M, Rooyackers A, Liu L, Lai TW, Wu DC, Lu J, Tymianski M, Craig AM, Wang YT (2007) NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. *J Neurosci* 27:2846–2857. [CrossRef Medline](#)
- Lombardi LM, Zaghula M, Sztainberg Y, Baker SA, Klisch TJ, Tang AA, Huang EJ, Zoghbi HY (2017) An RNA interference screen identifies druggable regulators of MeCP2 stability. *Sci Transl Med* 9:eaf7588. [CrossRef Medline](#)
- Luo SX, Huang EJ (2016) Dopaminergic neurons and brain reward pathways: from neurogenesis to circuit assembly. *Am J Pathol* 186:478–488. [CrossRef Medline](#)
- Luo SX, Timbang L, Kim JJ, Shang Y, Sandoval K, Tang AA, Whistler JL, Ding JB, Huang EJ (2016) TGF-beta signaling in dopaminergic neurons regulates dendritic growth, excitatory-inhibitory synaptic balance, and reversal learning. *Cell Rep* 17:3233–3245. [CrossRef Medline](#)
- Martens LH, Zhang J, Barmada SJ, Zhou P, Kamiya S, Sun B, Min SW, Gan L, Finkbeiner S, Huang EJ, Faress RV Jr (2012) Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury. *J Clin Invest* 122:3955–3959. [CrossRef Medline](#)
- Miduturu CV, Deng X, Kwiatkowski N, Yang W, Brault L, Filippakopoulos P, Chung E, Yang Q, Schwaller J, Knapp S, King RW, Lee JD, Herrgard S, Zarrinkar P, Gray NS (2011) High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors. *Chem Biol* 18:868–879. [CrossRef Medline](#)
- Mierau SB, Patrizi A, Hensch TK, Fagioli M (2016) Cell-specific regulation of N-methyl-D-aspartate receptor maturation by *Mecp2* in cortical circuits. *Biol Psychiatry* 79:746–754. [CrossRef Medline](#)
- Morris EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A, Carr D, Deng

- Y, Jin W, Black S, Long B, Liu J, Dinunzio E, Windsor W, Zhang R, Zhao S, Angagaw MH, Pinheiro EM, Desai J, Xiao L, et al. (2013) Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. *Cancer Discov* 3:742–750. [CrossRef Medline](#)
- Paoletti P, Bellone C, Zhou Q (2013) NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. *Nat Rev Neurosci* 14:383–400. [CrossRef Medline](#)
- Rodenas-Ruano A, Chávez AE, Cossio MJ, Castillo PE, Zukin RS (2012) REST-dependent epigenetic remodeling promotes the developmental switch in synaptic NMDA receptors. *Nat Neurosci* 15:1382–1390. [CrossRef Medline](#)
- Rönicke R, Mikhaylova M, Rönicke S, Meinhardt J, Schröder UH, Fändrich M, Reiser G, Kreutz MR, Reymann KG (2011) Early neuronal dysfunction by amyloid beta oligomers depends on activation of NR2B-containing NMDA receptors. *Neurobiol Aging* 32:2219–2228. [CrossRef Medline](#)
- Sgambato-Faure V, Cenci MA (2012) Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease. *Prog Neurobiol* 96:69–86. [CrossRef Medline](#)
- Shang Y, Doan CN, Arnold TD, Lee S, Tang AA, Reichardt LF, Huang EJ (2013) Transcriptional corepressors HIPK1 and HIPK2 control angiogenesis via TGF-beta-TAK1-dependent mechanism. *PLoS Biol* 11:e1001527. [CrossRef Medline](#)
- Tang M, Miyamoto Y, Huang EJ (2009) Multiple roles of beta-catenin in controlling the neurogenic niche for midbrain dopamine neurons. *Development* 136:2027–2038. [CrossRef Medline](#)
- Terasaki Y, Sasaki T, Yagita Y, Okazaki S, Sugiyama Y, Oyama N, Omura Matsuoka E, Sakoda S, Kitagawa K (2010) Activation of NR2A receptors induces ischemic tolerance through CREB signaling. *J Cereb Blood Flow Metab* 30:1441–1449. [CrossRef Medline](#)
- von Engelhardt J, Coserea I, Pawlak V, Fuchs EC, Köhr G, Seeburg PH, Monyer H (2007) Excitotoxicity in vitro by NR2A- and NR2B-containing NMDA receptors. *Neuropharmacology* 53:10–17. [CrossRef Medline](#)
- Wei G, Ku S, Ma GK, Saito S, Tang AA, Zhang J, Mao JH, Appella E, Balmain A, Huang EJ (2007) HIPK2 represses beta-catenin-mediated transcription, epidermal stem cell expansion, and skin tumorigenesis. *Proc Natl Acad Sci U S A* 104:13040–13045. [CrossRef Medline](#)
- Wiggins AK, Wei G, Doxakis E, Wong C, Tang AA, Zang K, Luo EJ, Neve RL, Reichardt LF, Huang EJ (2004) Interaction of Brn3a and HIPK2 mediates transcriptional repression of sensory neuron survival. *J Cell Biol* 167:257–267. [CrossRef Medline](#)
- Zhang J, Pho V, Bonasera SJ, Holtzman J, Tang AT, Hellmuth J, Tang S, Janak PH, Tecott LH, Huang EJ (2007) Essential function of HIPK2 in TGFbeta-dependent survival of midbrain dopamine neurons. *Nat Neurosci* 10:77–86. [CrossRef Medline](#)
- Zhang SJ, Zou M, Lu L, Lau D, Ditzel DA, Delucinge-Vivier C, Aso Y, Descombes P, Bading H (2009) Nuclear calcium signaling controls expression of a large gene pool: identification of a gene program for acquired neuroprotection induced by synaptic activity. *PLoS Genet* 5:e1000604. [CrossRef Medline](#)
- Zipfel GJ, Babcock DJ, Lee JM, Choi DW (2000) Neuronal apoptosis after CNS injury: the roles of glutamate and calcium. *J Neurotrauma* 17:857–869. [CrossRef Medline](#)